Literature DB >> 18803912

Novel medications to treat addictive disorders.

Iván D Montoya1, Frank Vocci.   

Abstract

Recent discoveries about the effects of drugs of abuse on the brain and the mechanisms of their addictions; new chemical compounds, including immunotherapies; and new actions of available medications are offering many opportunities for the discovery and development of novel medications to treat addictive disorders. Furthermore, advancements in the understanding of the genetic and epigenetic basis of drug addiction and the pharmacogenetics of the safety and/or efficacy of the medications are providing opportunities for more individualized pharmacotherapy approaches. Although multiple medications have been investigated for treating addictions, only a handful have shown acceptable safety and efficacy and are approved by the US Food and Drug Administration. This article reviews the current medications that are medically safe and have shown promising results for treating opioid, cocaine, methamphetamine, and cannabis addictions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18803912      PMCID: PMC2610431          DOI: 10.1007/s11920-008-0063-9

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  46 in total

1.  Human therapeutic cocaine vaccine: safety and immunogenicity.

Authors:  Thomas R Kosten; Marc Rosen; Julian Bond; Michael Settles; John St Clair Roberts; John Shields; Lindsay Jack; Barbara Fox
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

2.  Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.

Authors:  Charles A Dackis; Kevin G Lynch; Elmer Yu; Frederick F Samaha; Kyle M Kampman; James W Cornish; Amy Rowan; Sabrina Poole; Lenae White; Charles P O'Brien
Journal:  Drug Alcohol Depend       Date:  2003-05-01       Impact factor: 4.492

Review 3.  Neuroplasticity in the mesolimbic dopamine system and cocaine addiction.

Authors:  M J Thomas; P W Kalivas; Y Shaham
Journal:  Br J Pharmacol       Date:  2008-03-17       Impact factor: 8.739

4.  Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.

Authors:  Margaret Haney; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Stephanie Collins Reed; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2007-12-27       Impact factor: 4.530

Review 5.  Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.

Authors:  Ziva D Cooper; Margaret Haney
Journal:  Addict Biol       Date:  2008-02-14       Impact factor: 4.280

Review 6.  New treatments for cocaine dependence: a focused review.

Authors:  Laurent Karila; David Gorelick; Aviv Weinstein; Florence Noble; Amine Benyamina; Sarah Coscas; Lisa Blecha; William Lowenstein; Jean Luc Martinot; Michel Reynaud; Jean Pierre Lépine
Journal:  Int J Neuropsychopharmacol       Date:  2007-10-10       Impact factor: 5.176

7.  Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.

Authors:  Steven Shoptaw; Keith G Heinzerling; Erin Rotheram-Fuller; Trevor Steward; Jason Wang; Aimee-Noelle Swanson; Richard De La Garza; Tom Newton; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2008-05-12       Impact factor: 4.492

8.  Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers.

Authors:  Richard De La Garza; Steve Shoptaw; Thomas F Newton
Journal:  Int J Neuropsychopharmacol       Date:  2008-02-04       Impact factor: 5.176

9.  Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.

Authors:  Sharon L Walsh; Eric C Strain; George E Bigelow
Journal:  Addiction       Date:  2003-04       Impact factor: 6.526

10.  Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual.

Authors:  Catherine McGregor; Manit Srisurapanont; Amanda Mitchell; Wendy Wickes; Jason M White
Journal:  J Subst Abuse Treat       Date:  2008-03-07
View more
  10 in total

Review 1.  Glutamatergic medications for the treatment of drug and behavioral addictions.

Authors:  M Foster Olive; Richard M Cleva; Peter W Kalivas; Robert J Malcolm
Journal:  Pharmacol Biochem Behav       Date:  2011-04-22       Impact factor: 3.533

Review 2.  Epigenetics: a link between addiction and social environment.

Authors:  Duyilemi C Ajonijebu; Oualid Abboussi; Vivienne A Russell; Musa V Mabandla; William M U Daniels
Journal:  Cell Mol Life Sci       Date:  2017-03-02       Impact factor: 9.261

3.  Rapid access to morphinones: removal of 4, 5-ether bridge with Pd-catalyzed triflate reduction.

Authors:  Christopher D Hupp; John L Neumeyer
Journal:  Tetrahedron Lett       Date:  2010-04-28       Impact factor: 2.415

4.  Decreased reinforcing effects of cocaine following 2 weeks of continuous D-amphetamine treatment in rats.

Authors:  Keri A Chiodo; David C S Roberts
Journal:  Psychopharmacology (Berl)       Date:  2009-08-04       Impact factor: 4.530

5.  Abuse Potential of Oral Phendimetrazine in Cocaine-dependent Individuals: Implications for Agonist-like Replacement Therapy.

Authors:  B Levi Bolin; William W Stoops; Jeremy P Sites; Craig R Rush
Journal:  J Addict Med       Date:  2016 May-Jun       Impact factor: 3.702

Review 6.  The methamphetamine problem in the United States.

Authors:  Rachel Gonzales; Larissa Mooney; Richard A Rawson
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

7.  Buspirone reduces sexual risk-taking intent but not cocaine self-administration.

Authors:  B Levi Bolin; Joshua A Lile; Katherine R Marks; Joshua S Beckmann; Craig R Rush; William W Stoops
Journal:  Exp Clin Psychopharmacol       Date:  2016-06       Impact factor: 3.157

8.  Pharmacological treatment of cannabis dependence.

Authors:  A M Weinstein; David A Gorelick
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

9.  If there were an effective pharmacotherapy for cocaine use disorder, what would it do?

Authors:  Steven Shoptaw; Madhukar Trivedi; Jennifer S Potter
Journal:  Addiction       Date:  2020-12-02       Impact factor: 6.526

10.  Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence.

Authors:  Brian Reed; Eduardo R Butelman; Rebecca S Fry; Rachel Kimani; Mary Jeanne Kreek
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.